Brokerages forecast that Coherus Biosciences Inc (NASDAQ:CHRS) will announce earnings of ($0.45) per share for the current quarter, according to Zacks. Three analysts have issued estimates for Coherus Biosciences’ earnings. The lowest EPS estimate is ($0.52) and the highest is ($0.38). Coherus Biosciences posted earnings per share of ($0.74) during the same quarter last year, which suggests a positive year over year growth rate of 39.2%. The business is expected to report its next quarterly earnings report after the market closes on Thursday, May 9th.
According to Zacks, analysts expect that Coherus Biosciences will report full year earnings of ($1.44) per share for the current financial year, with EPS estimates ranging from ($1.74) to ($1.14). For the next year, analysts expect that the company will post earnings of ($0.56) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Coherus Biosciences.
Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings data on Thursday, February 28th. The biotechnology company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.10).
A number of equities analysts recently weighed in on CHRS shares. Credit Suisse Group set a $25.00 price objective on shares of Coherus Biosciences and gave the company a “buy” rating in a research report on Thursday, March 7th. Zacks Investment Research lowered shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research report on Monday, March 25th. BidaskClub upgraded shares of Coherus Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, January 31st. HC Wainwright initiated coverage on shares of Coherus Biosciences in a research report on Tuesday. They set a “buy” rating and a $28.00 target price on the stock. Finally, ValuEngine upgraded shares of Coherus Biosciences from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $28.00.
In other news, CFO Jean-Frederic Viret sold 3,000 shares of Coherus Biosciences stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $14.92, for a total transaction of $44,760.00. Following the completion of the transaction, the chief financial officer now owns 13,185 shares of the company’s stock, valued at approximately $196,720.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 18.20% of the company’s stock.
Several large investors have recently added to or reduced their stakes in CHRS. Legal & General Group Plc raised its stake in shares of Coherus Biosciences by 12.3% during the 4th quarter. Legal & General Group Plc now owns 9,095 shares of the biotechnology company’s stock worth $82,000 after buying an additional 998 shares during the last quarter. SG Americas Securities LLC acquired a new position in Coherus Biosciences in the 1st quarter valued at about $108,000. Roman Butler Fullerton & Co. acquired a new position in Coherus Biosciences in the 4th quarter valued at about $122,000. BNP Paribas Arbitrage SA raised its stake in Coherus Biosciences by 107,870.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,797 shares of the biotechnology company’s stock valued at $147,000 after purchasing an additional 10,787 shares during the last quarter. Finally, California Public Employees Retirement System acquired a new position in Coherus Biosciences in the 1st quarter valued at about $152,000. 94.77% of the stock is owned by institutional investors and hedge funds.
NASDAQ:CHRS opened at $16.12 on Monday. Coherus Biosciences has a 1-year low of $8.32 and a 1-year high of $20.66. The company has a debt-to-equity ratio of 8.29, a quick ratio of 2.49 and a current ratio of 2.54. The firm has a market capitalization of $1.11 billion, a P/E ratio of -5.01 and a beta of 3.64.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Recommended Story: What is the QQQ ETF?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.